SCOPUS 정보 검색 플랫폼

Volumn 12, Issue 1-2, 2002, Pages 165-172

Role of complement activation in hypersensitivity reactions to Doxil and HYNIC PEG liposomes: Experimental and clinical studies

(14) Szebeni, J a Baranyi, L a Savay, S a Milosevits, J a Bunger, R b Laverman, P c Metselaar, J M d Storm, G d Chanan Khan, A e Liebes, L e Muggia, F M e Cohen, R f Barenholz, Y f Alving, C R a

a WALTER REED ARMY INSTITUTE OF RESEARCH (United States)

b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES (United States)

c RADBOUD UNIVERSITY MEDICAL CENTER (Netherlands)

d UTRECHT UNIVERSITY (Netherlands)

e NEW YORK UNIVERSITY (United States)

f HEBREW UNIVERSITY OF JERUSALEM (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; DOXORUBICIN; DOXORUBICIN DERIVATIVE; HYDRAZINONICOTINATE PEGYLATED LIPOSOME TECHNETIUM TC 99M; LIPOSOME; PEGYLATED PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLETHANOLAMINE; STEALTH; UNCLASSIFIED DRUG;

ANAPHYLACTIC SHOCK; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CARDIOPULMONARY INSUFFICIENCY; CHILL; COMPLEMENT ACTIVATION; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TRANSPORT; DYSPNEA; FACE EDEMA; HEADACHE; HEMODYNAMICS; HUMAN; HUMAN CELL; HYPERSENSITIVITY REACTION; HYPERTENSION; HYPOTENSION; IMMUNOREACTIVITY; LIPID COMPOSITION; MEMBRANE VESICLE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SWINE; TACHYPNEA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COMPLEMENT ACTIVATION; DOXORUBICIN; HUMANS; LIPID METABOLISM; LIPOSOMES; NEOPLASMS; POLYETHYLENE GLYCOLS; SWINE; TECHNETIUM; TIME FACTORS;

EID: 0036339419 PISSN: 08982104 EISSN: None Source Type: Journal
DOI: 10.1081/LPR-120004790 Document Type: Conference Paper

Times cited : (189)

References (18)

1
- 0003015811
- Initial clinical evaluation of pegylated-liposomal doxorubicin in solid tumors
- Woodle, M.C., Storm, G., Eds.; Springer-Verlag and Landes Bioscience
- (1998) Long Circulating Liposomes: Old Drugs, New Therapeutics , pp. 155-174
- Gabizon, A.A.¹ Muggia, F.M.²

2
- 0035005359
- Pegylated liposomal doxorubicin: Metamorphosis of an old drug into a new form of chemotherapy
- (2001) Cancer Invest. , vol.19 , pp. 424-436
- Gabizon, A.A.¹

3
- 0035286282
- Liposomal encapsulated anthracyclines: New therapeutic horizons
- (2001) Curr. Oncol. Rep. , vol.3 , pp. 156-162
- Muggia, F.M.¹

4
- 0034793680
- Phase I study of doxil-cisplatin combination chemotherapy in patients with advanced malignancies
- (2001) Clin. Cancer Res. , vol.7 , pp. 3040-3046
- Lyass, O.¹ Hubert, A.² Gabizon, A.A.³

5
- 0028007310
- Clinical studies of liposome-encapsulated doxorubicin
- (1994) Acta Oncol. , vol.33 , pp. 779-786
- Gabizon, A.¹ Isacson, R.² Libson, E.³ Kaufman, B.⁴ Uziely, B.⁵ Catane, R.⁶ Ben-Dor, C.G.⁷ Rabello, E.⁸ Cass, Y.⁹ Peretz, T.¹⁰

6
- 0009884148
- Liposomal lipid-based formulations of amphotericin B
- (1996) Leukemia 10, Suppl , vol.2
- De Marie, S.¹

7
- 0009941681
- Safety assessment: DoxilR (Doxorubicin HC1 Liposome Injection) in refractory AIDS-related Kaposi's sarcoma
- Gardiner-Caldwell SynerMed, Califon, NJ
- (1996) Doxil Clinical Series , vol.1 , pp. 1-8
- Dezube, B.J.¹

8
- 0030696871
- Safety aspects of pegylated liposomal doxorubicin in patients with cancer
- (1997) Drugs 54, Suppl , vol.4 , pp. 30-45
- Alberts, D.S.¹ Garcia, D.J.²

9
- 0029038996
- Liposomal doxorubicin: Antitumor activity and unique toxicities during two complementary phase I studies
- (1995) J. Clin. Oncol. , vol.13 , pp. 1777-1785
- Uziely, B.¹ Jeffers, S.² Isacson, R.³ Kutsch, K.⁴ Wei-Tsao, D.⁵ Yehoshua, Z.⁶ Libson, E.⁷ Muggia, F.M.⁸ Gabizon, A.⁹

10
- 0028349925
- Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes
- (1994) Cancer Res. , vol.54 , pp. 987-992
- Gabizon, A.¹ Catane, R.² Uziely, B.³ Kaufman, B.⁴ Safra, T.⁵ Cohen, R.⁶ Martin, F.⁷ Huang, A.⁸ Barenholz, Y.⁹

11
- 0032700799
- Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small-cell lung cancer and head and neck cancer
- (1999) J. Clin. Oncol. , vol.17 , pp. 3512-3521
- Koukourakis, M.I.¹ Koukouraki, S.² Giatromanolaki, A.³ Archimandritis, S.C.⁴ Skarlatos, J.⁵ Beroukas, K.⁶ Bizakis, J.G.⁷ Retalis, G.⁸ Karkavitsas, N.⁹ Helidonis, E.¹⁰

12
- 33646421606
- Mountain View, CA, USA
- (2000) ALZA Pharmaceuticals Doxil Package Insert

13
- 0033639288
- 99m-PEG-liposomes for the evaluation of colitis in Crohn's disease
- (2000) J. Drug Target , vol.8 , pp. 225-233
- Brouwers, A.H.¹ De Jong, D.J.² Dams, E.T.³ Oyen, W.J.⁴ Boerman, O.C.⁵ Laverman, P.⁶ Naber, T.H.⁷ Storm, G.⁸ Corstens, F.H.⁹

14
- 0034521835
- The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil®)
- (2000) J. Liposome Res. , vol.10 , pp. 347-361
- Szebeni, J.¹ Baranyi, B.² Savay, S.³ Lutz, L.U.⁴ Jelezarova, E.⁵ Bunger, R.⁶ Alving, C.R.⁷

15
- 0021147157
- The membrane attack complex
- (1984) Spring. Sem. Immunopathol. , vol.7 , pp. 93
- Muller-Eberhard, H.J.¹

16
- 0032954323
- Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: A model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody
- (1999) Circulation , vol.99 , pp. 2302-2309
- Szebeni, J.¹ Fontana, J.L.² Wassef, N.M.³ Mongan, P.D.⁴ Morse, D.S.⁵ Dobbins, D.E.⁶ Stahl, G.L.⁷ Bünger, R.⁸ Alving, C.R.⁹

17
- 0033834805
- Liposome-induced pulmonary hypertension: Properties and mechanism of a complement-mediated pseudoallergic reaction
- (2000) Am. J. Physiol. , vol.279
- Szebeni, J.¹ Baranyi, B.² Savay, S.³ Bodo, M.⁴ Morse, D.S.⁵ Basta, M.⁶ Stahl, G.L.⁷ Bunger, R.⁸ Alving, C.R.⁹

18
- 0035660629
- Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents
- (2001) Crit. Rev. Ther. Drug Carr. Syst. , vol.18 , pp. 567-606
- Szebeni, J.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.